Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide

Raffaele De Caterina; Walter Ageno; Giuseppe Boriani; Paolo Colonna; Angelo Ghirarduzzi; Giuseppe Patti; Roberta Rossini; Andrea Rubboli; Piercarla Schinco; Giancarlo Agnelli

doi:10.1007/s12325-017-0488-9

Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide

Raffaele De Caterina, Walter Ageno, Giuseppe Boriani, Paolo Colonna, Angelo Ghirarduzzi, Giuseppe Patti, Roberta Rossini, Andrea Rubboli, Piercarla Schinco, Giancarlo Agnelli

Risultato della ricerca: Contributo su rivista › Articolo di review › peer review

Abstract

Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.

Lingua originale	Inglese
pagine (da-a)	620-637
Numero di pagine	18
Rivista	Advances in Therapy
Volume	34
Numero di pubblicazione	3
DOI	https://doi.org/10.1007/s12325-017-0488-9
Stato di pubblicazione	Pubblicato - 1 mar 2017
Pubblicato esternamente	Sì

Accesso al documento

10.1007/s12325-017-0488-9

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{7467bcfdf3fe4be8b0bcc93f100cfb72,

title = "Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide",

abstract = "Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.",

keywords = "Atrial fibrillation, Edoxaban, Non-vitamin K antagonist oral anticoagulants, Oral anticoagulants, Venous thromboembolism, Vitamin K antagonists",

author = "{De Caterina}, Raffaele and Walter Ageno and Giuseppe Boriani and Paolo Colonna and Angelo Ghirarduzzi and Giuseppe Patti and Roberta Rossini and Andrea Rubboli and Piercarla Schinco and Giancarlo Agnelli",

note = "Publisher Copyright: {\textcopyright} 2017, The Author(s).",

year = "2017",

month = mar,

day = "1",

doi = "10.1007/s12325-017-0488-9",

language = "English",

volume = "34",

pages = "620--637",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Adis",

number = "3",

}

TY - JOUR

T1 - Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers

T2 - A Practical Guide

AU - De Caterina, Raffaele

AU - Ageno, Walter

AU - Boriani, Giuseppe

AU - Colonna, Paolo

AU - Ghirarduzzi, Angelo

AU - Patti, Giuseppe

AU - Rossini, Roberta

AU - Rubboli, Andrea

AU - Schinco, Piercarla

AU - Agnelli, Giancarlo

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.

AB - Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.

KW - Atrial fibrillation

KW - Edoxaban

KW - Non-vitamin K antagonist oral anticoagulants

KW - Oral anticoagulants

KW - Venous thromboembolism

KW - Vitamin K antagonists

UR - http://www.scopus.com/inward/record.url?scp=85012249761&partnerID=8YFLogxK

U2 - 10.1007/s12325-017-0488-9

DO - 10.1007/s12325-017-0488-9

M3 - Review article

SN - 0741-238X

VL - 34

SP - 620

EP - 637

JO - Advances in Therapy

JF - Advances in Therapy

IS - 3

ER -

Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide

Abstract

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo